These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19349863)

  • 1. Cholangiociliopathies: genetics, molecular mechanisms and potential therapies.
    Masyuk T; Masyuk A; LaRusso N
    Curr Opin Gastroenterol; 2009 May; 25(3):265-71. PubMed ID: 19349863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases.
    Urribarri AD; Munoz-Garrido P; Perugorria MJ; Erice O; Merino-Azpitarte M; Arbelaiz A; Lozano E; Hijona E; Jiménez-Agüero R; Fernandez-Barrena MG; Jimeno JP; Marzioni M; Marin JJ; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Banales JM
    Gut; 2014 Oct; 63(10):1658-67. PubMed ID: 24436140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.
    Masyuk TV; Masyuk AI; Torres VE; Harris PC; Larusso NF
    Gastroenterology; 2007 Mar; 132(3):1104-16. PubMed ID: 17383431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease.
    Masyuk T; Masyuk A; Trussoni C; Howard B; Ding J; Huang B; LaRusso N
    JHEP Rep; 2021 Oct; 3(5):100345. PubMed ID: 34568801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin analogues for treatment of polycystic liver disease.
    Gevers TJ; Drenth JP
    Curr Opin Gastroenterol; 2011 May; 27(3):294-300. PubMed ID: 21191289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNAs in cholangiociliopathies.
    Masyuk T; Masyuk A; LaRusso N
    Cell Cycle; 2009 May; 8(9):1324-8. PubMed ID: 19342876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease.
    Lee SO; Masyuk T; Splinter P; Banales JM; Masyuk A; Stroope A; Larusso N
    J Clin Invest; 2008 Nov; 118(11):3714-24. PubMed ID: 18949056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression.
    Masyuk TV; Lee SO; Radtke BN; Stroope AJ; Huang B; Banales JM; Masyuk AI; Splinter PL; Gradilone SA; Gajdos GB; LaRusso NF
    Am J Pathol; 2014 Jan; 184(1):110-21. PubMed ID: 24211536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic second-hit mutations leads to polycystic liver diseases.
    Banales JM; Munoz-Garrido P; Bujanda L
    World J Gastroenterol; 2013 Jan; 19(1):141-3. PubMed ID: 23326178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling.
    Masyuk TV; Masyuk AI; Lorenzo Pisarello M; Howard BN; Huang BQ; Lee PY; Fung X; Sergienko E; Ardecky RJ; Chung TDY; Pinkerton AB; LaRusso NF
    Hepatology; 2017 Oct; 66(4):1197-1218. PubMed ID: 28543567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.
    Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Masyuk AI; Gradilone SA; Gajdos GB; Chandok N; Bakeberg JL; Ward CJ; Ritman EL; Kiyokawa H; LaRusso NF
    Gastroenterology; 2012 Mar; 142(3):622-633.e4. PubMed ID: 22155366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Targets in Polycystic Liver Disease.
    Masyuk TV; Masyuk AI; LaRusso NF
    Curr Drug Targets; 2017; 18(8):950-957. PubMed ID: 25915482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycystic liver diseases.
    Onori P; Franchitto A; Mancinelli R; Carpino G; Alvaro D; Francis H; Alpini G; Gaudio E
    Dig Liver Dis; 2010 Apr; 42(4):261-71. PubMed ID: 20138815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target.
    Masyuk AI; Masyuk TV; Lorenzo Pisarello MJ; Ding JF; Loarca L; Huang BQ; LaRusso NF
    Hepatology; 2018 Mar; 67(3):1088-1108. PubMed ID: 29023824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and management of polycystic liver disease.
    Gevers TJ; Drenth JP
    Nat Rev Gastroenterol Hepatol; 2013 Feb; 10(2):101-8. PubMed ID: 23296249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management.
    Cnossen WR; Drenth JP
    Orphanet J Rare Dis; 2014 May; 9():69. PubMed ID: 24886261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease.
    Banales JM; Masyuk TV; Bogert PS; Huang BQ; Gradilone SA; Lee SO; Stroope AJ; Masyuk AI; Medina JF; LaRusso NF
    Am J Pathol; 2008 Dec; 173(6):1637-46. PubMed ID: 18988797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGR5 in the Cholangiociliopathies.
    Masyuk TV; Masyuk AI; LaRusso NF
    Dig Dis; 2015; 33(3):420-5. PubMed ID: 26045278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis.
    Gradilone SA; Habringer S; Masyuk TV; Howard BN; Masyuk AI; Larusso NF
    Am J Pathol; 2014 Mar; 184(3):600-8. PubMed ID: 24434010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD).
    Banales JM; Masyuk TV; Gradilone SA; Masyuk AI; Medina JF; LaRusso NF
    Hepatology; 2009 Jan; 49(1):160-74. PubMed ID: 19065671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.